PREVENTION AND TREATMENT OF THROMBOEMBOLIC EVENTS IN MEDICAL PATIENTS AND NEW ANTICOAGULANTS

REFERENCES

• Cohen AT (VIE Impact Assessment Group in Europe, VITAE). Venous Thromboembolism (VIE) in Europe:The number of VTE events and associated morbidity and mortality. Thromb Hae-most. 2007; 98:756–76
   PubMed Web of Science ®Google Scholar
• Shojania KG et al. Making Healthcare Safer:A Critical Analysis of Patient Safety Practices. Evidence Report No. 43 from the Agency for Healthcare Research and Quality. AHRQ Publica-tion No. 01-E058; (2001)
   Google Scholar
• Clagett, GP et al. Prevention of venous thromboembolism. Chest. 1998; 114(suppl),531S–560S
   Web of Science ®Google Scholar
• Sandler DA et al. Autopsy proven pulmonary embolism in hos-pital patients: are we detecting enough deep vein thrombosis? J R Soc Med 1989; 82: 203–205.
   PubMed Web of Science ®Google Scholar
• Stein PD, Henry JW. Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy. Chest 1995; 108:978–981.
   PubMed Web of Science ®Google Scholar
• Alikhan et al. Fatal pulmonary embolism in hospitalised patients: a necropsy review. Journal of Clinical Pathology 2004;57:1254–1257
   PubMed Web of Science ®Google Scholar
• Cohen AT, Edmonson RA, Phillips MJ, et al. The changing pattern of venous thromboembolic disease. Haemostasis 1996;26:65–71.
   PubMedGoogle Scholar
• Health Select Committee Second Report. UK Parliament .2005. Ch2.
   Google Scholar
• Leizorovicz A. Long-term consequences of deep vein thrombo-sis. Haemostasis. 1998;28 Suppl 3:1–7.
   PubMedGoogle Scholar
• Seagroatt V et al. Elective total hip replacement: incidence, emergency readmission rate, and postoperative mortality. BMJ. 1991 Dec 7;303(6815)1431–5.
   Google Scholar
• Prandoni et al. The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica. 1997 Jul-Aug;82(4):423–8.
   PubMed Web of Science ®Google Scholar
• Bergqvist D. New approaches to prevention of deep vein thrombosis. Thromb Haemost. 1997 Jul;78(1):684–8.
   PubMed Web of Science ®Google Scholar
• Hirsh J et al. Management of deep vein thrombosis and pul-monary embolism. A statement for healthcare professionals. Council on Thrombosis (in consultation with the Council on Cardiovascular Radiology), American Heart Association. Circu-lation. 1996 Jun 15;93(12):2212–45.
   PubMed Web of Science ®Google Scholar
• Collins et al. Reduction in fatal pulmonary embolism and ve-nous thrombosis by perioperative administration of subcu-taneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med. 1988 May 5;318(18)1 162–73.
   Google Scholar
• Nielsen HK et al. 178 fatal cases of pulmonary embolism in a medical department. Acta Med Scand. 1981;209(5):351–5.
   PubMed Web of Science ®Google Scholar
• Hauch O et al. Fatal pulmonary embolism associated with surgery. An autopsy study. Acta Chir Scand. 1990 Nov-Dec;156(11–12): 747-9.
   Google Scholar
• Sperry KL et al. Toward a population-based assessment of death due to pulmonary embolism in New Mexico. Hum Pathol. 1990 Feb;21(2)159–65.
   PubMed Web of Science ®Google Scholar
• Samama MM et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enox-aparin Study Group. N Engl J Med. 1999 Sep 9;341(11):793–800.
   PubMed Web of Science ®Google Scholar
• Leizorovicz A et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembo-lism in acutely ill medical patients. Circulation. 2004 Aug 17;1 10(7):874–9.
   Web of Science ®Google Scholar
• Cohen AT et al (ARTEMIS Investigators). Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 2006; 332: 325–329
   PubMed Web of Science ®Google Scholar
• Cohen et al. VTE risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. The Lancet, 2 February 2008; Volume 371(9610): 387–394.
   Web of Science ®Google Scholar
• Bates SM et al.Treatment of venous thromboembolism. Thromb Haemost. 1999 Aug;82(2):870–7.
   PubMed Web of Science ®Google Scholar
• Kearon C. Initial treatment of venous thromboembolism. Thromb Haemost. 1999 Aug;82(2):887–91.
   PubMed Web of Science ®Google Scholar
• Turkstra F et al. The treatment of deep vein thrombosis and pulmonary embolism. Thromb Haemost. 1997 Jul;78(1):489–96
   PubMed Web of Science ®Google Scholar
• Vena caval filters for the prevention of PE. Cochrane Database Syst Rev. Oct 2007
   Google Scholar
• Hutten B et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous throm-boembolism in relation to both malignancy and achieved in-ternational normalized ratio: a retrospective analysis. J Clin Oncol 2000;18:3078–83.
   PubMed Web of Science ®Google Scholar
• Ridker PM et al. Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism. April 10, 2003; 15 (348)1425–1434
   Google Scholar
• Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-in-tensity warfarin therapy with conventional-intensity warfarin therapy for longterm prevention of recurrent venous throm-boembolism. N Eng(' Med. 2003;349(7):631–639.
   PubMed Web of Science ®Google Scholar
• Barritt DW et al. Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. Lancet. 1960 Jun 18;1(7138)1309–12.
   Google Scholar
• Ginsberg JS. Management of venous thromboembolism. N Engl J Med. 1996 Dec 12;335(24)1816–28.
   Google Scholar
• Gallus A et al. Safety and efficacy of warfarin started early af-ter submassive venous thrombosis or pulmonary embolism. Lancet. 1986 Dec 6;2(8519)1293–6.
   Google Scholar
• Hull, RD et al. (American-Canadian Thrombosis Study Group). Low-Molecular-Weight Heparin vs Heparin in the Treatment of Patients With Pulmonary Embolism. Arch Intern Med 2000; (160): 229–236
   PubMed Web of Science ®Google Scholar
• Levine, M et al A Comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombo-sis. N EnglJ Med 1996;334,677–681
   PubMed Web of Science ®Google Scholar
• Dolovich, LR et al A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 2000;160,181–188
   PubMed Web of Science ®Google Scholar
• Geerts et al. Prevention of VTE. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. CHEST 2004; 126:338S–400S
   Google Scholar
• Donat F et al. The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet 2002;41(suppl):1–9)
   PubMed Web of Science ®Google Scholar
• Matisse Investigators. Subcutaneous fondaparinux versus in-travenous unfractionated heparin in the initial treatment of PE. N EnglJ Med. 2003;349: 1695–1702
   PubMed Web of Science ®Google Scholar
• BLiller HR, Davidson BL, Decousus H, et al, Matisse Investiga-tors. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep vein thrombosis: a randomized trial. Ann Intern Med. 2004;140(11):867–873
   PubMed Web of Science ®Google Scholar
• British National Formulary 58, 2009
   Google Scholar
• Xarelto® Summary of Product Characteristics - EU, October 200841.
   Google Scholar
• Koopman, MM, Prandoni, P, Piovella, F, et al Treatment of ve-nous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home: the Tas-man Study Group. N EngIJ Med 1996;334,682–
   PubMed Web of Science ®Google Scholar
• Lee, AY et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Eng(' Med 2003;349,146–153.
   PubMed Web of Science ®Google Scholar